ISSN: 2329-8790
+44 1478 350008
Lucia Stanciakova, Miroslava Dobrotova, Pavol Holly, Peter Kubisz, Jan Stasko
National Centre of Haemostasis and Thrombosis, Department of Haematology and Transfusion Medicine, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, Slovakia
Scientific Tracks Abstracts: J Hematol Thrombo Dis
Abstract: Antithrombin is a representative of the natural anticoagulants. It is an inhibitor of thrombin and activated forms of coagulation factors IX, X, XI, XII, kalikrein and plasmin. Deficiency of antithrombin represents 3-7-fold increased risk of the venous thromboembolism in the comparison with other thrombophilic states. This clinical finding may be inherited or acquired. Heritable antithrombin deficiency is a rare thrombophilia inherited in autosomal dominant manner.The authors aim to present a clinical case reports of patients with challenging management of repeated thrombotic complications and antithrombin deficiency. In the discussed patients, repeated thrombotic complications were developed. Additionally, the authors discuss etiopathogenesis, diagnosis and treatment possibilities of this thrombophilic state. Antithrombin deficiency is a high-risk thrombophilia and a rare clinical state. Despite full anticoagulation, repeated thrombosis may occur and can have severe clinical consequences. Therefore, close monitoring of the affected patients is inevitable.This study complies with the Declaration of Helsinki and informed consent of the patient included in the study was obtained.
Lucia Stanciakova, MD, PhD. was awarded the degree Doctor of Medicine in 2013 and completed her postgraduate study in 2017. Now she works as a haematologist and assistant lecturer at the National Centre of Haemostasis and Thrombosis, Department of Haematology and Transfusion Medicine, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Slovakia. Her research interest includes thrombophilic states and their genetics, haemostasis in vascular disorders and oncological diseases, high-risk pregnancy, monitoring of the effectiveness of direct oral anticoagulants and antiplatelet treatment.